Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP), a company engaged in licensing proprietary technology for the delivery of bioactive compounds, including cannabinoids, was recently spotlighted in an article on Technical420.com. The publication highlighted, in detail, several of the company’s key developments and growth catalysts. “During the last few months, Lexaria has improved its fundamental story through the following developments: 1) The company applied for a new patent from the U.S., 2) Lexaria has advanced its agreements and launched new businesses, 3) Expands its Reach into Asia, 4) Focused on R&D with major organizations, and 5) The company’s cash position has improved significantly and has fully funded new initiatives.”
Lexaria Bioscience Corp. is a biosciences company with a proprietary technology for improved delivery of bioactive compounds. The Company’s lipophilic enhancement technology has been proven to enhance the bioavailability of orally ingested cannabinoids, while also improving taste. This technology promotes healthy ingestion methods, lower overall dosing and higher effectiveness in active molecule delivery. The Company’s technology is patent-protected for cannabidiol (CBD) and all other non-psychoactive cannabinoids, and patent-pending for Tetrahydrocannabinol (THC), other psychoactive cannabinoids, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules. For more information, visit http://www.LexariaEnergy.com
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.